Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) is now available.
Hangzhou Tigermed Consulting has called its 2026 First H Share Class Meeting for June 2, 2026 in Hangzhou, following its 2025 annual general meeting and the 2026 first A share class meeting. H shareholders on the register as of that date may attend, vote by poll, or appoint proxies, subject to standard registration and documentation procedures.
At the meeting, investors will vote on a special resolution to grant the board a general mandate to repurchase H shares, requiring approval by at least two-thirds of the voting rights present. The proposed buyback authority, if approved, would give the company greater flexibility in capital management and may have implications for share liquidity and capital structure for H shareholders.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$55.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a China-based contract research organization serving the pharmaceutical and biotech sectors with clinical research and related services. The company is listed in Hong Kong via H shares and targets both domestic and international drug development clients seeking outsourced R&D support.
Average Trading Volume: 1,814,582
Technical Sentiment Signal: Sell
Current Market Cap: HK$49.1B
Learn more about 3347 stock on TipRanks’ Stock Analysis page.